Skip to main content

Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis

Read the press release here
  • About Us
    • Company Overview
    • Leadership
    • Recent News Coverage
    • Corporate Responsibility
  • Pipeline
  • Our Companies
  • Our Trials
  • For Investors
    • Overview
    • Stock Information
    • Events & Presentations
    • Press Releases
    • SEC Filings
    • Annual Reports
    • Corporate Governance
    • Analyst Coverage
    • Email Alerts
  • Join Us
  • About Us
    • Company Overview
    • Leadership
    • Recent News Coverage
    • Corporate Responsibility
  • Pipeline
  • Our Companies
  • Our Trials
  • For Investors
    • Overview
    • Stock Information
    • Events & Presentations
    • Press Releases
    • SEC Filings
    • Annual Reports
    • Corporate Governance
    • Analyst Coverage
    • Email Alerts
  • Join Us
LinkedIn Twitter

© 2025 Roivant Sciences Ltd. All Rights Reserved

Privacy Policy Terms of use Legal
Document
Form 8937 (Sept. 2023).pdf (628.26 KB)

 

Document
Form 8937 (Sept. 2021).pdf (1.95 MB)

Interested in Joining Us?

Join the team changing the future of healthcare. A career at Roivant is filled with remarkable growth opportunities for those tackling the most significant challenges in science and technology.

See available positions

Pipeline

Our Companies

Join Us

Contact Us

New York

151 W 42nd Street
15th Floor
New York, NY 10036
United States

Boston

451 D Street
Boston, MA 02210
United States

Basel

Viaduktstrasse 8
4051 Basel
Switzerland

© 2025 Roivant Sciences Ltd. All Rights Reserved

Privacy policy

Terms of use

Legal